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Summary: A critical evaluation of the determination of acid phosphatase of prostatic origin with the Du Pont ACA
is reported. The affinity of the enzyme towards certain substrates, and the specificity of sodium thymolphthalein
monophosphate as a substrate for prostatic acid phosphatase were investigated. The validity of this method, which is
supposed to be specific for prostatic phosphatase is, however, limited; clinical data showed that related human acid
phosphatases interfere and decrease the specificity of the determination.
Die Bestimmung der sauren Prostata-Phosphatase mit dem Automatic Clinical Analyzer (ACA, Du Pont)
Zusammenfassung: Die Bestimmung der sauren Prostata-Phosphatase mit dem Du Pont ACA wurde einer kritischen
Beurteilung unterzogen. Sowohl die Affinität des Enzyms für bestimmte Substrate als auch die Spezifität von Na-
trium-thymolphthalein-monophosphat als Substrat für saure Prostata-Phosphatase wurde untersucht. Der Wert dieser
Methode, von der behauptet wird, für saure Prostata-Phosphatase spezifisch zu sein, ist jedoch beschränkt; verwandte
saure Phosphatasen des Menschen stören eine spezifische Bestimmung, wie durch klinische Untersuchungen bewiesen
wurde.
Introduction It is claimed that the Du Pont Automatic Clinical Analy-
t . . , __ . zer ACA1) measures quantitatively the acid phosphataseSince the findings of Gutman et al (1) and Huggms &
 pf prostatic origin> and that the substrate used (sodium
Hodges (2) that serum acid phosphatase (EC 3.1. 3.2) thymolphthalein monophosphate) is more specific for
activity is markedly increased in patients with prostatic ^
 prostatic enzyme than other currently used substrates,
carcinoma, determination of this enzyme activity has
 With the introduction of this instrument into our labora-
been widely used in the detection of prostatic cancer
 tory $ ft was therefore of interest to examine whether the
and in monitoring the therapy of this disease (3).
 method distinguishes between closely related, but differ-
A number of procedures, involving different substrates, ent phosphatases, and to test whether the method gives
buffers, or variations of other conditions such as inhibi- reliable results,
tors (4), have been used for the assay of prostatic acid
phosphatase in serum. Despite these variations, any assay
based on the measurement of catalytic activity is subject i; £ L de Du Pont Nempurs and Co. (Inc.), Instruments
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Materials and Methods
Reagents and equipment
The reagents for the enzyme assays were from E. Merck or J. T.
Baker Chemical. The substrate, sodium thymolphthalein mono-
phosphate, was from Sigma Chemical Co, and the DEAE A-SO
Sephadex from Pharmacia Sweden.
Acid phosphatase reagent packs for the assay of acid phosphatase
of prostatic origin were obtained from Du Pont de Nemours. The
pack contains 2.4 μπιοί sodium thymolphthalein monophos-
phate.
Acid phosphatase of piostatic origin was automatically deter-
mined with the ACA. All operations are automated except the
introduction of the sample. The test result is obtained after
about 7 minutes. The enzyme activities are expressed in Du Pont
International Units.
Procedures
Enzyme determinations
1.1 The acid phosphatase with p-nitrophenyl phosphate as sub-
strate was measured as follows: assay mixtures contained
routinely, unless otherwise indicated, 0.5 ml p-nitrophenyl
phosphate (11 mmol/1) in 0.1 mol/l sodium acetate (pH 5.5)
and 0.1 ml enzyme solution. After incubation for 15 min at
37 °C the reaction was stopped by addition of 8 ml 0.2 mol/l
NaOH and the absorbance of the solution was measured at
401 nm (5). One unit of activity (V) is defined as the amount of
enzyme which liberates 1 μπιοί p-nitrophenol per min under
conditions mentioned above.
1.2 Acid phosphatase activity towards α-naphthyl phosphate
was determined as outlined below: The assay mixture consisted
of 0.4 ml 5 mmol/1 α-naphthyl-phosphate and 0.1 ml enzyme
solution both in 0.1 mol/l sodium acetate (pH 5.5). After incuba-
tion (15 min; 37 °C) the reaction was stopped by adding 0.1 ml
of a solution containing 1.25 g/1 Fast Red B in 5 mmol/1 H2SO4
followed by 0.8 ml 0.2 mol/l NaOH. The absorbance of the solu-
tion was measured at 600 nm. One unit of acid phosphatase was
defined as the amount of enzyme which liberates 1 Mmol of
o-naphthol per min under the above conditions.
1.3 Acid phosphatase activity towards sodium thymolphthalein
monophosphate was measured as follows: 0.2 ml enzyme solu-
tion was added to 1 ml 3 mmol/1 sodium thymolphthalein mono-
phosphate in 0.1 mol/l sodium acetate (pH 5.5), containing 5 g
Brij-35 per liter of buffered substrate (6). After incubation
(30 min; 37 °C) the reaction was stopped and the color developed
with 5 ml of a solution containing 50 mmol/1 each of sodium
carbonate and sodium hydroxide. The absorbance was measured
at 590 nm. One unit of enzyme activity is the amount of enzyme
which liberates 1 μηιοί of thymolphthalein per min under the
above conditions.
2. Routinely the enzyme determinations were performed in so-
dium acetate (pH 5.5). Since the ACA method is an adaptation
of the thymolphthalein monophosphate hydrolysis method in
citrate buffer, we also performed the above assays in 0.1 mol/l
sodium citrate.
Crude enzyme preparation of prostatic origin
Fresh, human prostatic tissue was the source of enzyme. After
excission the gland was frozen and stored at - 20 °C. All further
procedures were carried out at + 4 °C. An extract of the prostatic
tissue was prepared as follows, the frozen prostate gland was
sliced into thin sections and these were added to 200 ml 0.1 mol/l
sodium acetate (pH 5.5). The mixture was homogenized in a
Waring Blendor (15.000 X g; 30 min) and the supernatant was
decanted and used for further experiments.
Crude enzyme preparation of human erythrocytes
One half liter of fresh blood was centrifuged at 10000 g
for 10 min at 4 °C. After removing the plasma and the leuco-
cytes the residue was washed three times with cold physio-
logical saline. The erythrocytes were hemolyzed with four
volumes of 5 mmol/1 sodium acetate pH 5.5 containing
0.25 ml/1 Triton X-100. After standing for 15 min the solution
was centrifuged (30000 g for 30 min at 4 °C). The supernatant
was dialyzed against 1 mmol/1 sodium acetate (pH 5.5) for
24 hours at 4 °C followed by concentration against polyethylene
glycol. From the concentrated dialyzed hemolysate (100 ml),
20 ml was applied to a DEAE sephadex A-50 column (50 X
0.5 cm). Hemoglobin was eluted from the column in the cold
with 100 ml cold equilibration buffer, 1 mmol/1 sodium acetate
(pH 5.5). Chromatography was continued with a linear gradient
of sodium acetate (pH 5.5), followed by elution of the column
with 1 mol/l NaCl. Fractions of 3 ml were collected, while the
flow rate was 3 ml per hour. The fractions were assayed for acid
phosphatase activity with p-nitrophenyl phosphate as the sub-
strate. The enzymatically active fractions were pooled, con-
centrated and used for further experiments.
Acid phosphatase of the spleen
A crude preparation of human splenic tissue was prepared
essentially as described for the prostatic preparation.
Results
Characterization of the prostatic enzyme preparation
With p-nitrophenyl phosphate as substrate, the phos-
phatase activity of the crude prostatic extract was in-
hibited 98% by 10 mmol/1 L-tartrate. This confirms the
identity of the prostatic phosphatase, and is in agreement
with other authors (4).
The enzyme was also inactivated by ferric ions, as already
reported by other authors (7). Inhibition was 95%, 40%
and 15% with 1.0,0.5 and 0.25 mmol/1 ferric chloride,
respectively. The inhibition by Ζ,-tartrate was also studied
over a range of substrate concentrations (10 mmol/1—
10 μπιοΙ/1) yielding an inhibition constant KI =
35 μιηοΐ/ΐ. This value is in agreement with those obtained
by Kilsheimer&Axelrod (8).
Substrate specificity of the prostatic enzyme preparation
Km values for various substrates in acetate buffer were
determined by zLineweaver-Burk plot (9), and the
results are summarized in table 1.
These values indicate that our prostatic enzyme prepara-
tion has a higher affinity for the substrate a-naphthyl
phosphate than for sodium thymolphthalein monophos-
phate.
Tab. 1. Km values of the acid phosphatase of prostatic tissue
towards different substrates.
The substrate concentration in these experiments varied
from 10 μπιοΐ/ΐ to 2 mmol/1. Other conditions were as
described under Materials and Methods. The buffers used
are 0.1 mol/l sodium acetate (pH 5.5) and 0.1 mol/l
sodium citrate (pH 5.95).
Substrate Km
(mmol/1)
Sodium Sodium
acetate citrate
A-naphthylphosphate 0.13 0.39
p-nitrophenylphosphate . 0.33 0.50
Sodium thymolphthalein mpnpphpsphate 0.80 1.20
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Since the AC A method is an adaptation of the method
of Roy et al (6), who originally used citrate buffer, we
repeated the Km determinations in this buffer. These
results are also shown in table 1; again, the enzyme
shows highest affinity for α-naphthylphosphate.
Interference by other acid phosphatases
The above results do not exclude the possibility that
prostatic acid phosphatase is specific for sodium thymol-
phthalein monophosphate. We therefore isolated the
acid phosphatase of human erythrocytes by DEAE
Sephadex chromatography. Three separated and distinct
peaks of acid phosphatase were obtained, as already
described (10). The three peaks were combined for
further study. Erythrocytic acid phospHatase prepara-
tion (20 U/l by the α-naphthylphosphate method) was
mixed with an equal volume of serum from a healthy
woman containing negligible acid phosphatase as deter-
mined with the ACA. Acid phosphatase activity was then
determined with the ACA. We repeated the experiment
with an erythrocytic acid phosphatase preparation con-
taining 5.0 U/l. The results in table 2 clearly show inter-
ference by erythrocytic acid phosphatase in the deter-
mination of prostatic acid phosphatase with the Du Pont
ACA. Similar experiments with the splenic acid phos-
phatase also showed interference by this enzyme in the
determination of prostatic acid phosphatase (table 2).
Thus, the determination of acid phosphatases of pro-
static origin with the Du Pont ACA is influenced by
other phosphatases.
To verify these findings, we determined acid phosphatase
with the Du Pont ACA in 35 cancer patients (20 men,
15 women), including patients with multiple myeloma,
various leukemias, various bone disorders,Hodgkin 's
disease, thrombocytaemia, but not prostatic cancer.
Tab. 2. Experiments to investigate the specificity of the Du Pont
ACA.
To 1 ml serum of a healthy woman, with negligible acid
phosphatase activity determined with the ACA, was
added 1 ml of an erythrocytic acid phosphatase prepara-
tion containing 200 U/l determined with the a-naphthyl-
phosphate method. In the mixture the activity was
determined with the ACA, The experiment was repeated
with addition of an erythrocytic acid phosphatase pre-
paration containing 5.0 U/l. Above experiments were
also performed with an acid phosphatase preparation
from the spleen, at the same levels of addition.
Enzyme activities determined with the ACA are expressed
in Du Pont International Units per liter (IU/1). The
normal range is 0-0.8 IU/1.
Added acid
phosphatase
Erythrocytic
Splenic
Initial
activity
[iU/11
0.16
0.16
0.16
0.16
Activity
added
[U/l]
20.0
5.0
20.0
5.0
Final
activity
[IU/1]
2.34
0.58
9.80
2.52
In 5 specimens the result was higher than the norm. One
of the elevated samples (5.6 IU/1) was from a woman
with adenocarcinoma with metastases.
Discussion
The high specificity of enyzmes, that is to say, the strict
limitation of the action of each enzyme to one substrate
or to a very small number of closely related substances
is one of their most striking characteristics. Although the
prostate is by far the richest source of acid phosphatase,
this Enzyme is found in all cells that contain lysosomes.
Therefore it is not surprising that increased acid phospha-
tase in serum has been found in a number of diseases
other than prostatic carcinoma. Significant elevation of
serum acid phosphatase has been observed in patients
with Gaucher's disease,· myeloma, leukemia, thrombo-
cytosis, osteogenic sarcoma and various bone disorders
involving osteoclastic activity (11). Differentiation of
prostatic acid phosphatases from the enzymes derived
from other tissues has received attention in various
studies. In the study of Roy et al (6) it has been shown
that thymolphthalein monophosphate is more specific
than phenylphosphate, α-naphthylphosphate and
p-nitrophenylphosphate for prostatic acid phosphatase,
whereas a similar specificity for the enzyme from erythro-
cytes, liver, kidney, bone and platelets is lacking. In
their clinical studies no falsely positive results were
obtained with this substrate in the sera of non prostatic
cancer patients. Their results were confirmed partly
by Foti et al (12) who reported thymolphthalein mono-
phosphate to be the most specific substrate for prostatic
acid phosphatase. However, they reported 26% false
positives from non prostatic cancer patients determined
with their enzymatic assay, leaving undecided whether
these above normal results also were obtained with the
substrate sodium thymolphthalein monophosphate. Li
et al (11) came to the conclusion that both α-naphthyl-
phosphate and thymolphthalein monophosphate were
good but not specific substrates for prostatic acid
phosphatase.
In view of these reports, together with our knowledge
of acid phosphatase (5,13), and the fact that we were
interested in the quantitative measurement the acid
phosphatase of prostatic origin, the ACA method was
further investigated. We confirmed both the /,-tartrate
(4) and ferric ion (7) inhibition of our prostatic enzyme.
In carrying out a specificity study it is usual to select a
reference substrate, which is generally the most readily
attacked biological substrate and to work out optimum
conditions for this. Other possible substrates are then
examined under the same conditions of pH, temperature
and concentration. In our case we used the conditions of
the ACA method, which are based on an adaptation of
the method of Roy et al (6).
One can clearly conclude from the results of our kinetic
experiments, that the affinity of acid phosphatase of
J. Clin. Chem. Clin. Biochem. / Vol. 18, 1980 / No. 10
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prostatic origin is higher for -naphthylphosphate than
for the substrate sodium thymolphthalein monophos-
phate. These results also indicate that the enzyme in-
vestigated here, acid phosphatase of prostatic origin, is
not a very specific one because it is acting on several
related substrates. Bearing this in mind, and the fact
that the acid phosphatases from erythrocytes and
spleen hydrolyse the substrate sodium thymolphthalein
monophosphate (tab. 2), this picture of a method which
quantitatively measures the acid phosphatase of prostatic
origin becomes severely blurred. We can conclude that
the method proposed by the manufacturers of the ACA
is indeed an assay system for acid phosphatase of prosta-
tic origin, but that it is subject to interference by other
phosphatases and its value as a quantitative procedure
for prostatic acid phosphatase is limited.
This is supported by our clinical studies on the ACA. It
is apparent from the acid phosphatase activities found
in patients of non-prostatic origin, that the substrate is
not completely specific for the prostatic form of the
enzyme. We have no explanation for the discrepancy
between the clinical findings of Roy et al (6), who found
no values above the norm in sera of non-prostatic cancer
patients, and our results. We do not believe that it is a
result of a minor modification in the adaptation of the
thymolphthalein monophosphate method on the ACA;
Li et al (11) also reported a patient with elevated acid
phosphatase activity as determined with the sodium
thymolphthalein monophosphate method.
From the literature it is already clear that the substrates
used to measure serum acid phosphatase in prostatic
cancer patients, including phenylphosphäte, p-nitro-
phenylphosphate, jS-glycerophosphate, phenolphthalein
diphosphate and -naphthylphosphate, are not specific
for acid phosphatase of prostatic origin; our results
show that sodium thymolphthalein monophosphate is
also hydrolyzed by various acid phosphatases.
The clinical usefulness of this enzyme determination, is
thus limited, but a further complicating factor is the
great instability of the catalytic activity of the enzyme
"(14).
An immunological measurement, with its accompanying
high specificity, would therefore be preferable. The
results of the immunological measurement of prostatic
acid phosphatase are promising (12,15).
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